Article Details
Retrieved on: 2024-11-13 21:41:38
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details Sutro Biopharma’s Q3 2024 financial results and developments in their antibody-drug conjugate (ADC) technologies, including collaborations and trials with bevacizumab. Tags and key concept highlight Sutro's focus on advancing biopharma innovation.
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here